Drug interactions
Ibrutinib + Rimegepant
Severity: Moderate
Ibrutinib and Rimegepant: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ibrutinib inhibits intestinal P-glycoprotein and may raise rimegepant exposure. Higher levels could increase adverse effects such as nausea and hypersensitivity reactions.
What this interaction means in plain words
Ibrutinib and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ibrutinib belongs to Oncology; Rimegepant belongs to Central Nervous System.
Why it happens
Inhibition of P-glycoprotein efflux by ibrutinib increases rimegepant absorption.
What to do
Rimegepant labeling advises avoiding a repeat dose within 48 hours when it is taken with P-gp inhibitors. Monitor for adverse effects.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ibrutinib and Rimegepant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rimegepant
Other interactions of Ibrutinib
- Abciximab + Ibrutinib Major
- Acetylsalicylic acid + Ibrutinib Major
- Alteplase + Ibrutinib Major
- Amobarbital + Ibrutinib Major
- Apalutamide + Ibrutinib Major
- Apixaban + Ibrutinib Major
Frequently asked questions
Can I take Ibrutinib with Rimegepant?
MediHelp rates the interaction as moderate. Ibrutinib and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ibrutinib inhibits intestinal P-glycoprotein and may raise rimegepant exposure. Higher levels could increase adverse effects such as nausea and hypersensitivity reactions.
How serious is the interaction between Ibrutinib and Rimegepant?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Rimegepant labeling advises avoiding a repeat dose within 48 hours when it is taken with P-gp inhibitors. Monitor for adverse effects.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
